Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07296874 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acute Effects of Cannabis on Cognition and Affect

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints removed 29 → 27 primary endpoints
See other at-risk trials from Washington State University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 7 more changesShow less
    • Recruitment opened
    • Enrollment target: 90 to 92
    • Start date changed from estimate of Jul 2026 to Sep 11, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: 24 to 23
    • Study description shortened, about 298 words
    • Site details revised
  2. Start date: Feb 2026 to Jul 2026
    • Primary and study completion dates: Feb 2028 to May 2028
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will examine how a moderate dose of THC affects mood and cognitive functioning in regular cannabis users. The study uses a double-blind, placebo-controlled, crossover design, meaning each participant will complete two sessions. Specifically, each participant will be given active cannabis (20 mg THC) in one session, and placebo in the other session. The order will be randomized across participants, so half will receive cannabis first, and the other half will receive placebo first. Ninety two adults who use cannabis at least weekly will be recruited from the local community. After an online screening survey, eligible participants will attend a laboratory visit where the participants will provide informed consent and complete saliva and urine drug tests to confirm recent abstinence from cannabis and absence of other drugs. Participants who pass screening will complete baseline questionnaires of cannabis use patterns, depression, anxiety, ADHD symptoms, emotion regulation, affect, and demographic information. Cannabis and placebo materials (obtained from NIDA) will be vaporized using a Volcano vaporizer device. Participants will inhale the vapor under supervision, and neither the participant nor the researcher assessing outcomes will know which product is administered. After vaping, participants will complete repeated mood ratings and a battery of cognitive tests assessing executive functions like planning, inhibition, working memory, and cognitive flexibility. The participants will then watch a nature video and report their feelings of awe and affect. At the end of each session, participants will remain in a supervised room with entertainment and snacks until at least four hours have passed since vaping and the participants report feeling sober. The participants will then return for a second session with the opposite study condition (THC or placebo) one week later. Both sessions follow the same procedures. Participants are fully debriefed after completing the study.
Trial Details
NCT Number NCT07296874
Lead Sponsor Washington State University
Conditions
(from sponsor)		 Cannabis Use
Related terms Marijuana Abuse
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov